DEMENEGO acquired by VAM INVESTMENTS
Context
VAM Investments acquired an 80% majority stake in Demenego from the founding De Menego family. This primary buyout transaction was designed to facilitate the transition of the company from a family-run business to a managerially-led retail platform. The founding family reinvested to retain a 20% minority stake, ensuring a smooth leadership handover. The strategic rationale for the deal centers on accelerating the growth of the store network and professionalizing the corporate structure.
DEMENEGO, which reported an EBITDA margin of [members only] in 2019, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in 1960, Demenego is a historic Italian eyewear specialist and a leading chain of specialized optical centers in North-East Italy. The company operates a network of 39 stores and employs approximately 270 people, serving a loyal database of 630,000 registered clients. Its unique business model integrates high-level healthcare services with retail excellence, featuring state-of-the-art medical equipment for vision correction in every location. A distinctive innovation is the presence of "Demenego Labs" in all sales points, which utilize interconnected digital systems to produce customized glasses in just one hour. The group offers a vast range of over 4,500 models, combining its successful private label with major international third-party brands to ensure visual well-being and a modern omnichannel shopping experience.
Ent. Value
€10–30M
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with DEMENEGO
Other operations with DEMENEGO
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2024 | MONTEFIORE INVESTMENT | DEMENEGO | ITALY | Ophthalmology |
Similar deals in Health Providers
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2020 | INFRATIL | QSCAN GROUP | AUSTRALIA | Radiology |
| 10/2020 | KKR / TETHYS INVEST / ARDIAN / CNP ASSURANCES / MERIEUX EQUITY PARTNERS | ELSAN | FRANCE | Clinics / Hospitals |
| 09/2020 | EQT PARTNERS | COLISÉE | FRANCE | Nursing Homes |
| 07/2020 | ORPEA | BRINDLEY HEALTHCARE | IRELAND | Nursing Homes |
| 07/2020 | BIOGROUP | LABORIZON | FRANCE | Labs (Biology) |
| 06/2020 | ASKLEPIOS KLINIKEN | RHÖN-KLINIKUM | GERMANY | Clinics / Hospitals |
| 03/2020 | ORPEA | TLC GROUP | IRELAND | Nursing Homes |
| 02/2020 | AMUNDI PRIVATE EQUITY / SOCIETE GENERALE CAPITAL PARTENAIRES | VIVALTO VIE | FRANCE | Nursing Homes |
| 02/2020 | VIVALTO VIE | SOLIMAR | SPAIN | Nursing Homes |
| 02/2020 | CLARIANE | INICEA | FRANCE | Clinics / Hospitals |
REFERENCES
Revenue range: €10–30M
EBITDA range: €5–25M
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DEMENEGO by VAM INVESTMENTS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: vam investments